Vir Biotech to collaborate with Biogen for developing coronavirus treatment

Drug developer Vir Biotechnology Inc said on Thursday it had signed a letter of intent with Biogen Inc for the development of a potential coronavirus treatment, sending shares up 20%.
Data & News supplied by
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.